{"doi":"10.2217/fon.11.107","title":"Axitinib in the Treatment of Metastatic Renal Cell Carcinoma","abstract":null,"journal":"Future Oncology","year":2011,"id":633055,"datarank":0.5456379239589579,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":0.0,"self_endowment_contribution":0.5456379239589579,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":311967,"name":"Eric Jonasch","orcid":"0000-0003-0943-2806","position":1,"is_corresponding":false},{"id":1641161,"name":"Thai H Ho","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Axitinib in the Treatment of Metastatic Renal Cell Carcinoma","abstract":"Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.","is_dataset_classified":null,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22044199","pmcid":null,"openalex_id":"https://openalex.org/W2125311018","authors":[],"funders":[],"total_grants":0,"fwci":2.034,"citation_percentile":0.86871597,"influential_citations":0,"citation_trend":[{"year":2012,"count":5},{"year":2014,"count":4},{"year":2015,"count":7},{"year":2016,"count":4},{"year":2017,"count":1},{"year":2018,"count":2},{"year":2019,"count":2},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2024,"count":7}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon.11.107","host_type":"publisher"},{"url":"https://doi.org/10.2217/fon.11.107","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22044199","host_type":"repository"}],"fields_of_study":["Renal cell carcinoma treatment","Cancer Genomics and Diagnostics","Renal and related cancers"],"mesh_terms":["Axitinib","Antineoplastic Agents","Carcinoma, Renal Cell","Humans","Imidazoles","Indazoles","Kidney Neoplasms","Clinical Trials, Phase I as Topic","Clinical Trials, Phase II as Topic","Clinical Trials, Phase III as Topic","Receptors, Vascular Endothelial Growth Factor"],"keywords":["Axitinib","Medicine","Renal cell carcinoma","Tyrosine-kinase inhibitor","Oncology","Internal medicine","Tyrosine kinase","Carcinoma","Targeted therapy","Angiogenesis","Sunitinib","Cancer","Receptor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T10:51:44.239481Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}